

December 14, 2017

Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma announces
Organizational Realignment and Personnel Change

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada) today announced that the following organizational realignment and personnel change, effective January 1, 2018:

1. Organizational Realignment (effective January 1, 2018)

Drug Research (Division)

Genomic Science Laboratories is dissolved and its functions are transferred to Sumitomo Chemical Co., Ltd.

*Transfer of functions of Genomic Science Laboratories to Sumitomo Chemical Co., Ltd. is announced today jointly with Sumitomo Chemical Co., Ltd.

2. Personnel Change (effective January 1, 2018)

Drug Research (Division)

Position as of January 1, 2018	Current position	Name
Senior Director, Platform Technology Research Unit	Senior Director, Platform Technology Research Unit Senior Director, Genomic Science Laboratories	Hidetaka Nagata

Contact:

Public Relations/Investor Relations

Sumitomo Dainippon Pharma Co., Ltd.

TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)